In conclusion, this study does not concretely define the amount of PPD required and the number of lesions to be injected. In addition, there is uncertainty about how to decide the amount of PPD required in relation to the extent of the disease, whether to inject the same dosage in subsequent sittings and what to do if numbers of lesions reduce. More studies are needed to resolve these ambiguities.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Shaurya Rohatgi, Amit Shivaji Kerure, Satish Udare, Hemangi Rajiv Jerajani
Department of Dermatology, Venereology and Leprosy, MGM Medical College and Hospital, 1Consultant Dermatologist, Dr. Amit Kerure Skin Clinic, Navi Mumbai, Maharashtra, India

Address for correspondence: Dr. Shaurya Rohatgi, Department of Dermatology, Venereology and Leprosy, MGM Medical College and Hospital, Navi Mumbai, Maharashtra, India. E-mail: shaurya023@gmail.com

REFERENCES
1. Saoji V, Lade NR, Gadegone R, Bhat A. Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol 2016;82:42-6.
2. Nofal A, Nofal E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24:1166-70.
3. Shaheen MA, Salem SA, Fouad DA, El-Fatah AA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther 2015;28:194-200.
4. Abd-Elazeim FM, Mohammed GF, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. J Dermatolog Treat 2014;25:264-7.
5. Kerure AS, Nath AK, Oudeacoumar P. Intralesional immunotherapy with tuberculin purified protein derivative for verruca: A study from a teaching hospital in South India. Indian J Dermatol Venereol Leprol 2016;Feb 8.doi: 10.4103/0378-6323.175910.[Epub ahead of print]
6. Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol 2014;171:696-712.
7. Tubersol®: Tuberculin Purified Protein Derivative (Mantoux). Toronto, Ontario, Canada: Sanofi Pasteur Limited; 2013. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM114924.pdf [Last accessed on 2016 Feb 20].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Rohatgi S, Kerure AS, Udare S, Jerajani HR. Immunotherapy or not? The mystery deepens. Indian J Dermatol Venereol Leprol 2016;82:417-8.

Authors’ reply

Sir,

We thank the authors for their valuable comments. Immunotherapy is the treatment of disease by inducing, enhancing or suppressing immune response. In the context of the present study, it indicates the therapeutic stimulation of cell-mediated immunity for the treatment of warts. All the published studies which are based on stimulating cell-mediated immunity for the treatment of warts use the term immunotherapy even with different antigens and different doses schedule and even when given at multiple sites.\[1-6\] Purified protein derivative irrespective of the dosage protocol in the treatment of warts acts by stimulation of cell-mediated immunity; hence, immunotherapy is the right term to describe the present study.

We were unable to find any previous reports that indicate any specific principle or procedure of dose and sites to qualify as immunotherapy. Antigens injected or topically applied, even at multiple sites without fixed doses are well accepted as immunotherapy.\[1,6,7\] Immunotherapy for warts is a relatively new concept where the standardization has not yet been achieved. Hence, different studies have used different dose schedules.\[4-6\] It will require large-scale studies to develop standardization. However, before that the efficacy of immunotherapy for warts should be established. When we started using immunotherapy,
our preliminary observation (unpublished data) showed that using immunotherapy injections at multiple sites gave better results than injection at a single site; hence, we used injections at multiple sites. From the above letter, the success rate achieved by the authors using the fixed dose is not clear. Other workers, like us, reported good success with immunotherapy injections given at multiple sites.\(^1,6\) Not all the drugs used in dermatology have a fixed dose or dose schedule as this is decided by multiple factors such as disease severity and various other co-morbid conditions. The procedure we described is simple to practice where the number of sessions and the duration is fixed and the dose varies depending on the extent of involvement and hence, we think there is no reason for confusion.

Warts are known to clear spontaneously and the clearance rate without treatment (no manipulation) or with saline injection (placebo/ manipulation) is around 20%.\(^2,3,8\) Horn et al. and Nofal and Nofal, as quoted in our article, have shown that it is the specific effect of immunotherapy injection and not the effect of injection (tissue manipulation); hence, to consider that the injections in multiple lesions increase the cure rate by increasing the tissue manipulation goes against the present evidence.\(^2,3\)

All major illness including active tuberculosis which affect immunogenicity are excluded from our study. Treated tuberculosis was not considered as an exclusion criterion. Active or treated tuberculosis is not a contraindication for Mantoux testing for which purified protein derivative is used; in fact, Mantoux test is used for the clinical evaluation of tuberculosis. Hence, injecting purified protein derivative in patients with treated tuberculosis does not violate any safety precautions. In fact, the basis of choosing purified protein derivative for immunotherapy is the high prevalence of tuberculosis in the country which is likely to induce a good hypersensitivity response in most people. Furthermore, in some studies, immunotherapy was carried out only in those patients who were first confirmed to have a positive hypersensitivity response to the test antigen. Hypersensitivity response is important to get a response to immunotherapy. Side effects were noticed in some of our patients as shown in the photograph but the reaction was manageable confirming a good safety of purified protein derivative even if injected at multiple sites.

To conclude, our study showed that immunotherapy with injections of purified protein derivative at multiple sites is useful in treating warts.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

**Vikrant Saoji, Nitin Lade**

Department of Dermatology, Jawaharlal Nehru Medical College, Wardha, Department of Dermatology, Indira Gandhi Government Medical College and Hospital, Nagpur, Maharashtra, India

Address for correspondence: Dr. Vikrant Saoji, 22, Sukhad, Dandige Layout, Shankar Nagar, Nagpur - 440 010, Maharashtra, India.

E-mail: vikrantsaoji@hotmail.com

REFERENCES

1. Gupta S, Malhotra AK, Verma KK, Sharma VK. Intraleisional immunotherapy with killed Mycobacterium \(w\) vaccine for the treatment of ano-genital warts: An open label pilot study. J Eur Acad Dermatol Venereol 2008;22:1089-93.

2. Nofal A, Nofal E. Intraleisional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24:1166-70.

3. Horn TD, Johnson SM, Helm RM, Roberson PK. Intraleional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: A single-blinded, randomized, and controlled trial. Arch Dermatol 2005;141:589-94.

4. Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther 2011;24:137-43.

5. Wananukul S, Chatproedpras P, Kittiratsacha P. Intraleional immunotherapy using tuberculin PPD in the treatment of plantar warts in pregnant women. Asian Biomed 2009;3:739-43.

6. Meena JK, Malhotra AK, Mathur DK, Mathur DC. Intraleional immunotherapy with Mycobacterium \(w\) vaccine in patients with multiple cutaneous warts: Uncontrolled open study. JAMA Dermatol 2013;149:237-9.

7. van der Steen P, van de Kerkhof P, der Kinderen D, van Vlijmen I, Happle R. Clinical and immunohistochemical responses of planter warts to topical immunotherapy with diphenylcyclopentenone. J Dermatol 1991;18:330-3.

8. Lipke MM. An armamentarium of wart treatments. Clin Med Res 2006;4:273-93.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

---

Access this article online

Quick Response Code: [QR Code Image]

Website: [www.ijdvl.com](http://www.ijdvl.com)

DOI: 10.4103/0378-6323.182971

How to cite this article: Saoji V, Lade N. Authors’ reply. Indian J Dermatol Venereol Leprol 2016;82:418-9.

Received: March, 2016. Accepted: April, 2016.